Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTUTE: Aclidinium/Formoterol in COPD
NCT03181880Phase 4Withdrawn
- Sponsor
- AstraZeneca
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of aclidinium, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Planned start Dec 2017; status: withdrawn.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03181880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181880.